Fengjuan Xuan

Third Affiliated Hospital of Southern Medical University — China

Medicine · Health Sciences

21h-index8.0kcitations42works65.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(10), Atrial Fibrillation Management and Outcomes(6), Hemoglobinopathies and Related Disorders(6), Antiplatelet Therapy and Cardiovascular Diseases(5), Nematode management and characterization studies(5)

Publications42 total

Povetacicept for IgAN: Design of a Phase 3 Randomized, Placebo-Controlled Study
Journal of the American Society of Nephrology·2025
Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials
Advances in Therapy·2025· 2 citedOpen Access
Quantification of Vascular Remodeling and Sinusoidal Capillarization to Assess Liver Fibrosis with Photoacoustic Imaging
Radiology·2025· 18 cited
CO197 Vaso-Occlusion Definitions Can Impact Efficacy Assessments in Clinical Studies of Sickle Cell Disease
Value in Health·2024Open Access
Exagamglogene Autotemcel for Severe Sickle Cell Disease
New England Journal of Medicine·2024· 306 cited
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study
European Respiratory Journal·2023· 79 citedOpen Access
Differing Definitions of Vaso-Occlusion in Clinical Studies of Sickle Cell Disease Can Result in Differing Outcomes
Blood·2023
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Blood·2023· 32 cited
PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE
HemaSphere·2023· 1 citedOpen Access
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study
Journal of Cystic Fibrosis·2023· 112 citedOpen Access
170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study
Journal of Cystic Fibrosis·2022· 12 citedOpen Access
Triple Therapy for Cystic Fibrosis <i>Phe508del</i> –Gating and –Residual Function Genotypes
New England Journal of Medicine·2021· 254 citedOpen Access
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
American Journal of Respiratory and Critical Care Medicine·2021· 264 citedOpen Access
Combination of Multiple Hemodialysis Modes: Better Treatment Options for Patients Under Maintenance Hemodialysis
SHILAP Revista de lepidopterología·2021Open Access
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
The Lancet·2019· 1.3k citedOpen Access
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
New England Journal of Medicine·2019· 2.0k citedOpen Access
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two<i>F508del</i>alleles
ERJ Open Research·2019· 101 citedOpen Access
Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF homozygous for the F508DEL mutation
Ghent University Academic Bibliography (Ghent University)·2019· 2 cited
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
New England Journal of Medicine·2018· 322 citedOpen Access
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
New England Journal of Medicine·2018· 708 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

David L. Cutler(12), Jennifer L. Taylor‐Cousar(11), Marcus Mall(10), Bonnie W. Ramsey(10), Teddy Kosoglou(10), Edward F. McKone(9), Elizabeth Tullis(9), Samuel M. Moskowitz(9), Steven M. Rowe(9), Paul Statkevich(8), Neil Ahluwalia(7), C Simard(6), David Waltz(6), Haydar Frangoul(6), Franco Locatelli(6), Suzan Imren(6), James E. Schiller(6), Gautham Marigowda(5), Charlotte McKee(5), Simon Tian(5)